Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
01:23:59 EST Wed 17 Dec 2025
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

Q:PDSB - PDS BIOTECHNOLOGY CORPORATION - https://www.pdsbiotech.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
PDSB - Q0.80.879·1.220.50.901-0.0176-1.9355.62687290.92  0.93  0.87462.20  0.703518:52:43Dec 0915 min RT 2¢

Recent Trades - Last 10 of 729
Time ETExPriceChangeVolume
18:52:43Q0.94320.024650
18:22:37Q0.9157-0.002919
17:04:22Q0.8978-0.02085,000
16:29:55Q0.8999-0.018750
16:10:04Q0.901-0.01761
16:10:04Q0.901-0.01761
16:04:13Q0.901-0.01761
16:04:12Q0.901-0.01761
16:04:11Q0.901-0.01761
16:04:09Q0.901-0.01761

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-12-09 08:00U:PDSBNews ReleasePDS Biotech Announces New Composition of Matter Patent for PDS0101 in Japan
2025-12-02 08:30U:PDSBNews ReleasePDS Biotech Announces Scheduling of Type C Meeting with U.S. Food and Drug Administration ("FDA")
2025-11-13 07:30U:PDSBNews ReleasePDS Biotech Reports Third Quarter 2025 Financial Results and Provides Clinical Programs Update
2025-11-11 15:32U:PDSBNews ReleasePDS Biotechnology Announces up to $11.1 Million Registered Direct Offering
2025-11-10 08:30U:PDSBNews ReleasePDS Biotechnology Announces Translational Data Showing Strong Immunological and Clinical Activity of PDS0101 and PDS01ADC Presented at SITC 2025
2025-11-06 08:00U:PDSBNews ReleasePDS Biotech Announces Conference Call and Webcast for Third Quarter 2025 Financial Results
2025-10-30 08:00U:PDSBNews ReleaseNew Clinical and Translational Data on PDS Biotechnology's Novel Investigational Cancer Therapies PDS0101 and PDS01ADC to be Presented at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting
2025-10-29 08:37U:PDSBNews ReleasePDS Biotech to Seek Expedited Approval Pathway for PDS0101 in HPV16-Positive Head and Neck Cancer
2025-09-18 08:45U:PDSBNews ReleasePDS Biotech Sets Significant Benchmark in Head and Neck Cancer by Achieving Extended Survival in Low PD-L1 Expression (CPS 1-19) Cohort in VERSATILE-002 Trial, Potentially Eliminating Need for Chemotherapy in the Population
2025-09-02 08:00U:PDSBNews ReleasePDS Biotech to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
2025-08-25 08:30U:PDSBNews ReleasePDS Biotech Announces Final Topline Survival Data from VERSATILE-002 Phase 2 Trial in Head and Neck Cancer
2025-08-13 07:00U:PDSBNews ReleasePDS Biotech Reports Second Quarter 2025 Financial Results and Provides Clinical Programs Update
2025-08-06 08:00U:PDSBNews ReleasePDS Biotech Announces Conference Call and Webcast for Second Quarter 2025 Financial Results
2025-07-10 08:00U:PDSBNews ReleasePDS Biotech Announces Colorectal Cancer Cohort of Phase 2 Clinical Trial with PDS01ADC Met Criteria for Expansion to Stage 2 Following Positive Stage 1 Results
2025-06-09 08:00U:PDSBNews ReleasePDS Biotech to Host Key Opinion Leader Event to Discuss Versamune(TM) HPV for the Treatment of HPV16+ HNSCC
2025-06-02 08:00U:PDSBNews ReleasePDS Biotech Unveils Updated Positive Data From VERSATILE-002 Trial and Additional Trials Evaluating Versamune(TM) HPV to Treat Head and Neck Cancers at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
2025-05-22 17:27U:PDSBNews ReleasePDS Biotech Announces Positive Extended Follow-Up Data for VERSATILE-002 and Additional Trials Evaluating Versamune(TM) HPV to be Presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
2025-05-20 08:00U:PDSBNews ReleasePDS Biotech to Participate at the A.G.P. Virtual Annual Healthcare Company Showcase
2025-05-14 07:30U:PDSBNews ReleasePDS Biotech Reports First Quarter 2025 Financial Results and Provides Clinical Programs and Corporate Update
2025-05-09 16:05U:PDSBNews ReleasePDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)